Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. To aid in the development process, the Company incorporates its CNSProfile™, a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases

Company Growth (employees)
Type
Public
HQ
New York, US
Size (employees)
41 (est)
Intra-Cellular Therapies is headquartered in New York, US

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, US (HQ)
3960 Broadway

Intra-Cellular Therapies Data and Metrics

Intra-Cellular Therapies Financial Metrics

Intra-Cellular Therapies's revenue was reported to be $95.3 k in Q1, 2017
USD

Revenue (Q1, 2017)

95.3 k

Net income (Q1, 2017)

(26.9 m)

EBIT (Q1, 2017)

(27.8 m)

Market capitalization (18-Aug-2017)

482.4 m

Cash (31-Mar-2017)

23.6 m
Intra-Cellular Therapies's current market capitalization is $482.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.7 m577.3 k91.4 k330.7 k

Revenue growth, %

(79%)(84%)

R&D expense

21.2 m87.7 m93.8 m

General and administrative expense

10.3 m18.2 m24.8 m

Operating expense total

29 m31.6 m105.9 m118.6 m

EBIT

(26.3 m)(31 m)(105.8 m)(118.3 m)

EBIT margin, %

(960%)(5368%)(115816%)(35760%)

Interest expense

613 k7.1 k36.8 k

Interest income

29.6 k303.9 k1 m(2.9 m)

Pre tax profit

(30.7 m)(104.8 m)(115.4 m)

Income tax expense

(18 k)1.6 k1.6 k1.1 m

Net Income

(26.9 m)(30.7 m)(104.8 m)(116.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

219.2 k124.4 k3.3 k57.4 k124.4 k3.3 k228.4 k4.4 k95.3 k

R&D expense

2.7 m4 m18.6 m17.8 m28.5 m23.4 m25.3 m23.9 m21.5 m

General and administrative expense

2.1 m2.6 m3.8 m4 m3.9 m5.1 m6.5 m6.3 m6.3 m

Operating expense total

4.8 m6.6 m22.4 m21.7 m32.3 m28.5 m31.8 m30.2 m27.8 m

EBIT

(4.6 m)(6.5 m)(22.4 m)(21.7 m)(32.3 m)(28.5 m)(31.5 m)(30.2 m)(27.8 m)

EBIT margin, %

(2103%)(5227%)(675739%)(37796%)(26001%)(859664%)(13808%)(691985%)(29127%)

Interest expense

(2 k)(5 k)(2 k)(12.3 k)

Interest income

80.1 k88.1 k113.9 k179.6 k188.9 k656.4 k709.6 k763.9 k822.2 k

Pre tax profit

(26.9 m)

Income tax expense

(832.6 k)1.6 k

Net Income

(4.5 m)(6.4 m)(22.3 m)(21.5 m)(32.2 m)(27.8 m)(30.8 m)(30.3 m)(26.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

35.2 m61.3 m47.2 m48.6 m

Accounts Receivable

336.3 k51.6 k30.7 k94.3 k

Inventories

762.2 k1.3 m8 m4 m

Current Assets

38.2 m131 m483.3 m388.2 m

PP&E

68.3 k54.6 k775.5 k627.6 k

Total Assets

38.4 m131.1 m484.1 m388.9 m

Accounts Payable

3.4 m2.1 m1.6 m3.8 m

Current Liabilities

6.8 m10.6 m6.3 m10.5 m

Total Liabilities

13.4 m

Additional Paid-in Capital

89.2 m208.9 m669.9 m685.3 m

Retained Earnings

(57.6 m)(88.3 m)(193 m)(309.5 m)

Total Equity

31.6 m120.6 m476.2 m375.5 m

Financial Leverage

1.2 x1.1 x1 x1 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

91.1 m68.9 m100.8 m71.4 m332.8 m37.2 m52 m200.4 m23.6 m

Accounts Receivable

219.2 k124.4 k3.3 k9.1 k51.6 k98.2 k1.3 k68.2 k

Current Assets

141.2 m137.5 m236.5 m212.6 m512.3 m462.9 m446.8 m541.8 m371.6 m

PP&E

63.9 k57.4 k559.7 k722.1 k785.5 k731.4 k718.7 k677.7 k605.7 k

Total Assets

141.3 m137.6 m237.1 m213.4 m513.1 m463.7 m447.6 m542.6 m372.3 m

Accounts Payable

415.8 k503.9 k4.6 m4.9 m705 k2 m3.9 m5.4 m7.2 m

Current Liabilities

2.7 m3.6 m14.6 m9.3 m10.4 m8.9 m19.4 m140.7 m16.3 m

Additional Paid-in Capital

205.3 m207.2 m332.9 m335.7 m666.1 m673.7 m677.6 m681.5 m689.7 m

Retained Earnings

(66.6 m)(73.1 m)(110.5 m)(132.1 m)(164.2 m)(220.9 m)(251.7 m)(282 m)(336.4 m)

Total Equity

138.6 m134 m222.4 m203.6 m501.9 m452.7 m426 m399.3 m353 m

Financial Leverage

1 x1 x1.1 x1 x1 x1 x1.1 x1.4 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(30.7 m)(104.8 m)(116.4 m)

Depreciation and Amortization

25.5 k139.6 k196.9 k

Accounts Receivable

284.7 k20.9 k(63.7 k)

Accounts Payable

(1.3 m)(419.9 k)2.1 m

Cash From Operating Activities

(22.8 m)(102.3 m)(91.3 m)

Purchases of PP&E

(11.8 k)(860.6 k)(49 k)

Cash From Investing Activities

(66.7 m)(361.8 m)92.3 m

Cash From Financing Activities

115.7 m449.9 m477.7 k

Interest Paid

7.1 k7.1 k36.8 k

Income Taxes Paid

45 k1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.5 m)(6.4 m)(22.3 m)(21.5 m)(32.2 m)(27.8 m)(30.8 m)(30.3 m)(26.9 m)

Accounts Receivable

219.2 k124.4 k3.3 k9.1 k51.6 k98.2 k1.3 k68.2 k

Accounts Payable

415.8 k503.9 k4.6 m4.9 m705 k2 m3.9 m5.4 m7.2 m
USDY, 2017

Revenue/Employee

2.3 k

Financial Leverage

1.1 x

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80

Intra-Cellular Therapies Market Value History

Intra-Cellular Therapies Revenue Breakdown

Traffic Overview of Intra-Cellular Therapies

Intra-Cellular Therapies News and Updates

Why Intra-Cellular Therapies’ Stock Got Crushed Today

Its main drug couldn't beat a placebo.

Intra-Cellular Therapies Company Life and Culture

You may also be interested in